5,274 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Sei Investments Co.

Sei Investments Co. purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,274 shares of the biopharmaceutical company’s stock, valued at approximately $238,000.

Several other institutional investors have also recently made changes to their positions in the stock. Smartleaf Asset Management LLC lifted its stake in shares of PTC Therapeutics by 78.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 270 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of PTC Therapeutics in the fourth quarter worth approximately $68,000. R Squared Ltd purchased a new stake in shares of PTC Therapeutics in the fourth quarter worth approximately $79,000. KBC Group NV lifted its holdings in shares of PTC Therapeutics by 36.4% in the fourth quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 813 shares in the last quarter. Finally, Savant Capital LLC purchased a new position in shares of PTC Therapeutics during the fourth quarter valued at approximately $210,000.

Insider Activity at PTC Therapeutics

In other news, EVP Lee Scott Golden sold 897 shares of PTC Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total value of $42,114.15. Following the completion of the transaction, the executive vice president now owns 75,997 shares in the company, valued at $3,568,059.15. This trade represents a 1.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Elliott Boulding sold 1,333 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $66,783.30. Following the completion of the sale, the vice president now directly owns 105,515 shares in the company, valued at approximately $5,286,301.50. This trade represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,501 shares of company stock worth $1,546,088. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on PTCT shares. Morgan Stanley reissued an “overweight” rating and issued a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Scotiabank started coverage on shares of PTC Therapeutics in a report on Friday, March 7th. They issued a “sector perform” rating and a $55.00 target price for the company. Bank of America raised shares of PTC Therapeutics from an “underperform” rating to a “neutral” rating and raised their price target for the company from $41.00 to $55.00 in a research report on Tuesday, March 11th. Cantor Fitzgerald upped their price objective on shares of PTC Therapeutics from $76.00 to $113.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, Citigroup increased their price objective on shares of PTC Therapeutics from $32.00 to $45.00 and gave the company a “sell” rating in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.77.

PTC Therapeutics Stock Up 6.7 %

PTC Therapeutics stock opened at $42.98 on Friday. The firm has a 50 day moving average price of $50.48 and a 200-day moving average price of $45.82. PTC Therapeutics, Inc. has a twelve month low of $24.00 and a twelve month high of $58.38. The company has a market capitalization of $3.39 billion, a P/E ratio of -7.24 and a beta of 0.58.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.